SOLICITATION NOTICE
65 -- IV Fluids - MS-1011-07_IV_Fluids_FBO_Responses
- Notice Date
- 3/18/2011
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- Defense Logistics Agency, DLA Acquisition Locations, DLA Troop Support - Medical, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
- ZIP Code
- 19111-5096
- Solicitation Number
- MS-1011-07_IV_Fluids
- Archive Date
- 4/23/2011
- Point of Contact
- Kevin Hill, Phone: 210-292-3295, Jim Quinn, Phone: 210-292-3295
- E-Mail Address
-
kevin.w.hill@amedd.army.mil, james.e.quinn@amedd.army.mil
(kevin.w.hill@amedd.army.mil, james.e.quinn@amedd.army.mil)
- Small Business Set-Aside
- N/A
- Description
- Technical Requirement Responses to provide The Defense Medical Materiel Program Office (DMMPO) Medical Materiel Enterprise Standardization Office (MMESO) announces a Request for Incentive Agreement Quotation (RFIAQ) for the standardization of IV Fluids. The MMESO South is the lead MMESO for this project. The primary objective of this program is to standardize the quality of care across the MMESO North, South, West, Pacific, Europe (hereafter referred to as MMESOs) areas of responsibility (AOR) and operational assemblages based on the critical balance of clinical efficacy and value. This Standardization Action (SA) will apply to all MMESOs. It is intended for this initiative to result in the standardization of a technically and clinically preferred product (s) and source for institutional and operational medicine requirements at the best possible price. It is intended for this initiative to result in the reduction of Stock Keeping Units (SKUs) and National Stock Numbers (NSN). It is also intended that standardized products be obtained through the Department of Defense (DoD) Prime Vendor (PV) Program. As an enterprise-wide clinically driven program, vendors and products must meet specific technical requirements plus products must meet or exceed specific clinical performance requirements as a primary consideration. Among vendors who meet the technical requirements and the products that meet or exceed the clinical the clinical preferred threshold, best price will determine selection. It is intended that the selected vendor (s) for this SA support the enterprise goal of medical materiel standardization that combines operational and institutional requirements. The government is seeking a single award for this SA. The major facilities in the MMESOs include, but are not limited to MMESO North: Walter Reed Army Medical Center, National Naval Medical Center, Naval Medical Center Portsmouth, Wright-Patterson Medical Center; MMESO South Wilford Hall Medical Center, Brook Army Medical Center, Naval Hospital Jacksonville, Martin Army Community Hospital; MMESO West Naval Medical Center San Diego, Madigan Army Medical Center, Irwin Army Community Hospital, Mike O'Callaghan Federal Hospital; MMESO Pacific Tripler Army Medical Center, Honolulu, HI, 18th Medical Group, Kadena AB, Okinawa, US Naval Hospital, Yokosuka, Japan; MMESO Europe Landstuhl Regional Medical Center, Landstuhl, GE, US Naval Hospital, Naples, Italy, the 48th Medical Group, Lakenheath, UK; and Operational U.S. Forces. This standardization action is part of the Medical/Surgical PV program executed by the Defense Logistics Agency (DLA) Troop Support, Directorate of Medical Materiel. To participate, your company must have a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the current Med-Surg PV for each MMESO Area of Responsibility (AOR), i.e., Cardinal Health, and Owens & Minor. This requirement is pursuant to the DAPA clause by which DAPA holders agree to the standardization process and agree to allow PVs to distribute their products. The Incentive Agreement (IA) resulting from this RFIAQ is a supplement to the PV Program and is not a contract. For additional information regarding DLA Troop Support Medical's PV program please access its web site at https://dmmonline.dscp.dla.mil This IA standardization initiative will be a Three Phase IPP Process: vendor (s) who meets the technical / company requirements in Phase I will be invited to advance and participate Phase II where no-charge products will be provided for clinical evaluation and Phase III where pricing will be required for submittal. Phase II and Phase III will be conducted concurrently. The resulting IA will be for a base period of two (2) years (24 months) from date of selection with three (3) 12-month "option" periods not to exceed a total of 5 years. Anticipated selection date is July 2011. The selection will be based on the product and vendor that provides the Best Value to the enterprise. Products and vendors that meet or exceed the technical and clinical performance requirements will be considered clinically preferred products and sources. Among vendors who meet the technical requirements and the products that meet or exceed the clinically preferred standard, best price (i.e. lowest Aggregate Post Standardization Cost) will determine selection. Point of Contact: Mr. Kevin Hill, MMESO South, Team Leader, Kevin.w.hill@amedd.army.mil, 210-292-3270, Mr. Jim Quinn, Clinical Analyst, james.e.quinn@amedd.army.mil, 210-292-3295. B. Products & Performance Required. The MMESOs, are seeking product line items in the category of IV Fluids. Within the MMESOs, this product line has an estimated annual dollar requirement of $4,690,986.41. This forecast is based on historical Prime Vendor sales during a recent 12-month period. Based on the recent 12-month usage data, twenty-four (24) line items of the total one hundred forty-six (146) line items, account for 82.06% ($3,849,423.96) of the total volume in sales ($4,690,986.41) in the MMESOs, and are procurement significant. The top high volume usage lines for this project are shown in the Technical/Company Requirements below, consolidated by product type to reduce duplication within the top 24 lines. This represents the line item, or SKU, reduction that is an additional objective of this program. C. Instructions to Vendors Vendors interested in participating in this standardization initiative will provide an initial response to the FBO-posted RFIAQ to Mr. Kevin Hill, MMESO South, Team Leader, Kevin.w.hill@amedd.army.mil, 210-292-3270 Mr. Jim Quinn, Clinical Analyst, james.e.quinn@amedd.army.mil, 210-292-3295. The vendor's initial response will include detailed information requested in the technical/company requirements listed in the FBO RFIAQ and must also include: (1) Company name and address; (2) Company Point of Contact (POC) (Name and Phone Number, Fax Number, and E-mail address); and (3) Identification of the RFIAQ to which the vendor is responding. Due to the potential for e-mail to be lost in transmission, from network security, etc., vendor is strongly encouraged to confirm with the MMESO South that their initial submission, quote and literature actually arrived at the MMESO South via email. Each submitting vendor is advised to confirm receipt, allowing adequate time for resubmission before the due date / time, should a problem occur with the first submission. Vendor that does not meet the deadline of COB 5:00PM Central Standard Time (CST) on the date listed for closing (per the FBO RFIAQ), will be disqualified from further consideration in the standardization initiative. D. Source Selection Procedures The MMESO Tri-Service Product Review Board (TPRB) will serve as the forum for clinical recommendations for product selection, seeking and evaluating opportunities for committed volume purchase agreements, and coordinating logistics efforts in support of DoD Components. The boards are chaired by Designated Senior Logisticians (DSLs) and co-chaired by Designated Senior Clinicians (DSCs) in the MMESO AORs and include clinicians and logisticians for Medical Treatment Facilities (MTFs) within each MMESO. The Clinical Advisory Committee (CAC) members are the deciding officials for this initiative. The MMESO DSLs and DSCs intend to evaluate quotes and select a vendor on initial submissions/quotes. Vendor quotes should contain the vendor's best tiered-pricing discounts off the vendor's DAPA pricing based on committed volume of 80% of the total requirements of the MTFs in the MMESOs. The MMESO South reserves the right to conduct discussions and request revised quotes, if determined necessary. Phase I Technical / Company Requirements The MMESO CPT will review the responses from the vendor and determine whether vendor meets the technical/company requirements and determine acceptability. Vendor must meet the technical requirements for continued consideration in this initiative. Vendor who does not meet the requirements will be disqualified. Failure to provide any requested information or meet any of the technical requirements will disqualify the vendor from further consideration. A vendor who meets the following technical/company requirements will be qualified/invited to participate in the clinical/performance selection and will be requested to submit their best product/price discount quotes via an email communication. All communications of significant acquisition milestones (such as invitations to participate, or notices of disqualification) should be digitally signed. Technical/Company Requirements: During the acquisition planning process, the MMESO CPT validated/approved the equally weighted company/technical requirements outlined below. The five (5) requirements below must be answered with the vendor's initial submittal by the response date stated in the FBO announcement: 1. Vendor MUST provide a line of IV Fluids products that includes at a minimum the specific products and sizes identified below for IV Fluids and Admixture Solutions from the following categories; All products must be Latex Free. Sodium Chloride 0.9%, and Lactated Ringers. Vendor is required to supply all items listed in all sizes listed and will include at a minimum: Item Description SOLUTION IV SODIUM CHLORIDE 0.9% 1000ML SOLUTION IV LACTATED RINGERS 1000ML SOLUTION IV SODIUM CHLORIDE 0.9% 500ML SOLUTION IV SODIUM CHLORIDE 0.9% 250ML SOLUTION IV SODIUM CHLORIDE 0.9% 100ML SOLUTION IV SODIUM CHLORIDE 0.9% 50ML a. Vendor MUST provide a complete itemized list of items supplied (manufactured and/or distributed by brands and descriptions) via excel sheet, and product catalog & literature in response to this RFIAQ with initial submittal. Vendor is required to supply all items listed in all sizes and device types. (Vendor who does not have a complete product line as stated above will be disqualified in Phase I). b. Operational usage items are included in this list of IV Fluids. 2. Vendor MUST have a DAPA or be in the process of obtaining a DAPA for the IV Fluids product line. Vendor MUST provide the DAPA number with initial submittal or provide documentation that DAPA has been applied for with response submittal. Vendor without a DAPA number or who has not applied for a DAPA will be disqualified in Phase I. 3. Vendor MUST have agreements with the current Med/Surg Prime Vendors for each MMESO AOR, i.e. Cardinal Health and Owens & Minor for IV Fluids or be in the process of obtaining Prime Vendor agreements. Vendor must provide documentation to support agreements with initial submittal. Vendor whose products are not available through the Prime Vendors or who has not applied for PV distribution will be disqualified in Phase I. 4. Vendor MUST submit discounts off DAPA for the products included in this standardization initiative. (Note: vendor that fails to submit a discount from DAPA will be disqualified. Where lower FSS prices are available, DAPA holders are required by previous agreement to provide the FSS price as the DAPA price. Vendor shall not quote FSS prices as the discounted price for purposes of this standardization initiative. Vendor who does not provide discounts off DAPA in Phase III for ALL products will be disqualified.). 5. Vendor MUST provide IV Fluids products that are approved for use by the Food & Drug Administration (FDA). The IV Fluids products shall comply with the National Patient Safety Goals (NPSG), Universal Protocol (UP), and the Center for Disease Control & Prevention (CDC), Occupational Safety & Health Administration (OSHA) Standards, and provide literature to support this requirement with the initial submittals. Vendor who does not meet the above requirements or who fails to provide documentation to support these requirements will be disqualified in Phase I. Phase II Acceptability Evaluation Clinical Performance Clinical Performance Requirements Following acceptability of the technical/company requirements, the MMESO South, on behalf of the CPT, will request product sample sets from the product group to be sent to the CPT members at the participating MTFs. Vendor will be given 30 calendar days from the issue of the notice in which to deliver the product samples for clinical evaluation at Phase II. Product samples must be shipped to arrive at the designated addresses by 5:00PM local time for each MTF on the 30th calendar day after the notice to ship. Vendor MUST be able to deliver product literature, training materials and evaluation samples to the MMESO Pacific via FedEx or UPS AND to the MMESO Europe via United States Postal Service (USPS) and throughout the United States when requested in Phase II. Vendor who cannot or does not meet this requirement will be disqualified from the standardization process. Vendor must send the MMESO South verification regarding the shipment of literature and samples. This information will include the date of shipment, final delivery date, and tracking numbers and the carrier used by the vendor. Vendor will provide ONLY the following no cost product samples for clinical/performance evaluation. (Unused samples will not be returned). One case (1cs) or 12 bags each of IV Fluids samples listed below are to be provided to each of the evaluation sites that will be identified in the letters of invitation. Item to Send Number Each to send per MTF Size Item Description Solution IV Sodium Chloride 0.9% 1 case or 12 bags each 1000cc Solution IV Sodium Chloride 0.9% 1000ml The clinical/performance acceptability evaluation period will last for fourteen (14) calendar days. The acceptability evaluation will be conducted using the below listed requirements with responses as either a "YES" (meets/passes requirements) or "NO" (does not/fails to meet requirements) answers. The MMESO TPRB has established that the Clinically Preferred threshold of products for standardization will be eighty percent (80%) of the requirements questions answered as "YES" (meets/passes requirements). Vendor scoring below the clinically preferred threshold will be disqualified from selection for this standardization initiative. Of those vendors that are qualified as clinically preferred, selection will be based on best price. Vendor that has been disqualified will be notified in writing upon disqualification. Clinical /performance evaluations by the participating CPT facilities will be tabulated resulting in one score per participating MMESO per vendor. The participating MMESOs' scores by vendor will then be combined resulting in one final vendor performance evaluation score. All clinical/performance evaluations will be tabulated by the MMESO South, and results will be forwarded to the MMESO CPT for final review. Each MTF will evaluate the IV Fluids products with the below listed requirements. Each requirement for IV Fluids will be evaluated by two (2) trials (each clinical trial site will have at least two (2) clinical evaluators who will each evaluate all samples one time) in a non-clinical/non-patient setting. There will be approximately eight (8) MTFs enterprise wide that will be evaluating products. Clinical/Performance Requirements: During the acquisition planning process, the MMESO CPT validated/approved the clinical/performance requirements outlined below: 1. Container labeling is easy to read and includes type of fluid, volume gradient and expiration date. 2. The fluid container is optically clear, making it easy to determine the condition of the fluid. 3. The solution is easily accessible via container access port. 4. After container is spiked, the tubing remains secure with no leaking. Phase III Pricing Analysis Price Analysis Upon completion of the Phase I - Technical/Company Requirements, a vendor who is found technically acceptable will be qualified /invited to provide product samples and price discount quotes concurrently. Vendor will be given 30 calendar days from the date of pricing requests to submit IA pricing quotes, in a prescribed electronic spreadsheet format, based upon the requirements of the MMESOs. Pricing will be submitted to the MMESO South and must be received by 5:00 PM CST, thirty (30) calendar days after the issue date of the vendor notice to submit best price quotes. Vendor quotes should contain the vendor's best product matches for the specific products requested in this announcement. The MMESO DSLs and DSCs intend to evaluate quotes and select a vendor on initial submissions/quotes. Vendor quotes should contain the vendor's best tiered-pricing discounts off the vendor's DAPA pricing for the products identified in this announcement (based on committed volume of 80% of the total requirements of the MTFs in the MMESOs. Price will be analyzed based on the projected Aggregate Post-Standardization costs for each vendor. Aggregate Post-Standardization Cost will be calculated for each vendor by applying the vendor's offered prices to the anticipated annual usage of the enterprise. Unmatched items will be represented in the Post-Standardization Cost at a baseline non-discounted price (current DAPA price of product with highest procurement). Among the products and sources that were determined to be clinically preferred, the best price Aggregate Post-Standardization Cost will be selected.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DLA/J3/DSCP-M/MS-1011-07_IV_Fluids/listing.html)
- Place of Performance
- Address: Medical Materiel Enterprise Standardization Offices General Dynamics Information Technology (GDIT), 7800 IH-10 West, Suite 220, San Antonio, Texas, 78230-4768, United States
- Zip Code: 78230-4768
- Zip Code: 78230-4768
- Record
- SN02404595-W 20110320/110318234634-e7420a0d3204033d8bb943b4f4f0af70 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |